News
ACOG
9.13
+5.31%
0.46
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NASDAQ · 3d ago
Major Investor Ramps Up Position in Alpha Cognition Inc., Signaling Renewed Confidence
TipRanks · 5d ago
Alpha Cognition Inc trading resumes
TipRanks · 6d ago
Alpha Cognition Inc trading halted, volatility trading pause
TipRanks · 6d ago
Weekly Report: what happened at ACOG last week (0727-0731)?
Weekly Report · 6d ago
Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains?
NASDAQ · 07/28 10:55
Weekly Report: what happened at ACOG last week (0720-0724)?
Weekly Report · 07/27 10:20
Major Investor Doubles Down on Alpha Cognition With Bold New Stake
TipRanks · 07/25 02:02
Playing The Biotech Breakout With Insiders
Seeking Alpha · 07/23 19:15
Time to Jump In? Raymond James Is Bullish on These 2 Stocks
TipRanks · 07/23 09:57
Fourteen new option listings and one option delisting on July 22nd
TipRanks · 07/22 12:30
Alpha Cognition’s RESOLVE Study: Fresh Real‑World Data on Zunveyl in Alzheimer’s Care
TipRanks · 07/20 16:30
Weekly Report: what happened at ACOG last week (0713-0717)?
Weekly Report · 07/20 10:16
Weekly Report: what happened at ACOG last week (0706-0710)?
Weekly Report · 07/13 10:18
This Travelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 07/10 11:49
Alpha Cognition Price Target Announced at $20.00/Share by Raymond James
Dow Jones · 07/10 11:03
Raymond James Initiates Coverage On Alpha Cognition with Outperform Rating, Announces Price Target of $20
Benzinga · 07/10 10:53
Alpha Cognition initiated with an Outperform at Raymond James
TipRanks · 07/10 10:15
Weekly Report: what happened at ACOG last week (0629-0703)?
Weekly Report · 07/06 10:22
These low-priced stocks are flashing overbought signals
Seeking Alpha · 07/03 12:05
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.